英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
leggen查看　leggen　在百度字典中的解释百度英翻中〔查看〕
leggen查看　leggen　在Google字典中的解释Google英翻中〔查看〕
leggen查看　leggen　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    FDA approval history for Libtayo (cemiplimab-rwlc) used to treat Squamous Cell Carcinoma, Basal Cell Carcinoma, Non Small Cell Lung Cancer Supplied by Sanofi
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    Libtayo® (cemiplimab-rwlc) Approved in the U S as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
  • FDA Approves Libtayo for Cutaneous Squamous Cell Carcinoma . . .
    The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation, the agency has announced Effectiveness of the drug was determined in the C-POST randomized, double-blind, multicenter, placebo-controlled trial of 415 patients
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation
  • FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy . . .
    Cemiplimab (Libtayo; Regeneron Pharmaceuticals) has been approved as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at high risk of recurrence after
  • label - accessdata. fda. gov
    LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • FDA Approvals Roundup: Libtayo | RAPS
    FDA Approvals Roundup: Libtayo A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA) New indications Libtayo gets extended indication for NSCLC with high PD-L1 expression Regeneron’s Libtayo (cemiplimab-rwlc injection) has been approved as a first-line therapy for advanced non‒small cell lung cancer (NSCLC) in patients whose tumors have high
  • FDA Approves Libtayo as First Immunotherapy for Adjuvant . . .
    FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of CSCC Libtayo® (cemiplimab-rwlc) Approved in the U S as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation





中文字典-英文字典  2005-2009